[Skip to Content]
[Skip to Content Landing]
Views 239
Citations 0
Health Agencies Update
February 28, 2017

Public-Private Partnership Speeds Investigator Access to Cancer Drugs

Author Affiliations

Copyright 2017 American Medical Association. All Rights Reserved.

JAMA. 2017;317(8):797. doi:10.1001/jama.2017.1089

A new collaboration between pharmaceutical and biotech companies and the National Cancer Institute (NCI) at the National Institutes of Health aims to get cancer drugs into the hands of researchers—and patients—faster. The NCI Formulary will allow NCI-Designated Cancer Center investigators to move quickly through the process to access drugs for preclinical studies and clinical trials.

The program launched in January with a suite of 15 approved and investigational drugs from 6 pharmaceutical companies, including Bristol-Myers Squibb, Eli Lilly and Company, and Genentech. Under the arrangement, participating companies must approve or reject investigator proposals within 60 days—a process that can typically take up to 18 months.

First Page Preview View Large
First page PDF preview
First page PDF preview